AI-designed, physics-triaged therapeutics for rare and metabolic disease
HELSINKI, Finland — SAN FRANCISCO, CA & ATHENS, OH — June 2, 2026 — Rayca Precision and ASAKE Biotechnology today announced a strategic research and development collaboration to design, triage, and advance AI-generated therapeutics across rare and metabolic diseases. The partnership integrates Rayca’s physics-aware AI drug discovery engine with ASAKE’s translational capabilities in biosynthetic technology, synthetic chemistry, and emerging modalities, with the goal of rapidly progressing multi-modal assets (linear and macrocyclic peptides as well as small molecules) into preclinical development and future partnering.
Read the full press release on BioPharma Dive:
